Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma

NEXT STORY
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
PREV STORY
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Premiers Gather with Nurses Unions & Mental Health Commission for Health Briefing

EDMONTON, Alberta, July 18, 2017 (GLOBE NEWSWIRE) -- The Canadian Federation of Nurses Unions ...

author_avatar
NASDAQ Market News

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal ...

author_avatar
NASDAQ Market News

Achaogen Unveils Data Highlighting the Effectiveness of Plazomicin Against MDR Gram-Negative Bacteria at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

-- Evaluation of EPIC Phase 3 data demonstrates sustained clinical cure with plazomicin compared ...

author_avatar
NASDAQ Market News